PRESS RELEASE: Axion BioSystems make REPROCELL a product distributor

Axion BioSystems, Inc., the world leader in multi-well microelectrode array (MEA) systems, has announced REPROCELL as the new distributor of its Maestro systems and consumables in Japan.

Continue reading 

Headaches could have impaired the success of potential cancer drug AMG 337; human tissue studies rescued it

It is not uncommon that at a late-stage of drug development (especially during the clinical testing) unforeseen toxicities and/or poor efficacy are observed. This is often, but not only, due to the limitations of the off-target screening used by pharma (the so-called secondary pharmacology). Although still useful for quickly screening a relatively high number of potential off-target hits, these screening studies, often used by pharmaceutical companies, are in the form of a proprietary set of in vitro methods biased and/or tailored for the specific molecule background of the drug candidate. Often, this does not allow evaluation in a clinical context and can contribute to the high rate of drug failures (attrition rate) at a later stage of the drug discovery process. This is a costly “Achilles heel” for the pharmaceutical industry[1].

Continue reading 

TISSUE SPOTLIGHT: Lung

This issue, we are casting the REPROCELL Tissue Spotlight on the LUNG.

The lungs are the central organs of the human respiratory system enabling you to take around 25,000 breaths a day — mostly, without any conscious thought that you are doing so!

Continue reading 

Improving patient outcomes through collaboration

The return on R&D investments in the UK is at its lowest rate in nine years, despite Britain’s global presence in science, technology and health. Pharmaceutical attrition rates continue to rise, and the UK biotech landscape remains fragmented. Medicines Discovery Catapult (MDC) aims to connect the UK R&D community more effectively by putting the patient at the heart of the drug discovery process. As part of our collaboration with the MDC, REPROCELL have pledged to provide custom drug discovery assays using live human tissues.

Continue reading 

Tissue Sourcing for the Development of iPSC-derived Disease Models

Human induced pluripotent stem cells (iPSCs)-based models are an ideal resource for studying disease mechanisms in vitro at the cellular level[1], screening potential new therapeutics[2], and investigating the propensity and mechanism for the development of toxic side effects caused by drug treatment[3]. Such iPSC-based models enable studies to be performed under defined experimental conditions and in a reproducible manner.

Continue reading 

TISSUE SPOTLIGHT: Skin

In this issue, we are casting the REPROCELL Tissue Spotlight on the SKIN.

In humans, the largest organ in the body is the skin layer, accounting for up to 15% of the total body weight and a surface area of up to 2m2. It is composed of several layers — the epidermis, dermis and the sub-cutaneous layer, the hypodermis — each crucial to the many functions of the skin ranging from a protective barrier for internal tissues and organs, through regulation of body temperature and nutrient absorption, to the generation of vitamin D.

Continue reading 

TISSUE SPOTLIGHT: Intestines

In this issue, we are casting the REPROCELL Tissue Spotlight on the INTESTINES.

The intestines (large and small) are vital organs in the gastrointestinal tract of our digestive system. Comprising a winding muscular tube extending from the stomach to the anus the main purpose is to digest food and absorb nutrients. The intestines also have a key role to play in the processes of cellular messaging, fighting infection and in regulating the body’s water balance.

Continue reading 

The Human Touch: meeting clinical needs in IBD research

There is a clinical need for novel therapies in Inflammatory Bowel Disease. Current research is however limited by models which do not physiologically mimic the disease in humans. REPROCELL’s Human IBD Fresh Tissue Assay is the most clinically relevant IBD model on the market and the only commercially available assay of its kind.

Continue reading 

New publication by Roche on diarrheal toxicity induced by anti-HER2/3 combination therapy includes REPROCELL human fresh tissue data

A publication in Molecular Cancer Therapeutics has shed new light on the mechanisms by which anti-HER2/3 combination therapies can cause diarrhea.

Continue reading 

Human Tissue Experts REPROCELL Launch New Customized Primary Cell Isolation Services

REPROCELL’s BioServe and Biopta tissue procurement networks combine to create a new service isolating human primary cells.

Continue reading